On Apr. 10, 2010, Genentech opened its $400 million manufacturing center in Hillsboro, Oregon. The 75-acre property campus is home to a state-of-the-art fill/finish facility and warehousing and distribution center. The site located 20 miles west of Portland houses Hillsboro Technical Operations (HTO), which is Roche’s primary manufacturing site for U.S. drug products, and Hillsboro Individualized Therapies (HIT), which accelerates the development and manufacturing of cell and gene therapies to transform lives.

In addition to manufacturing drug product on three state-of-the-art filling lines, HTO provides finished goods packaging, a distribution center that currently serves one third of the Roche U.S. market and tank management serving the Roche global drug substance network. Together, HTO and HIT employ more than 600 people.

In 2015, the company announced plans to invest more than $125 million in the expansion of its fill/finish facility. Genentech was founded in April 1976 by venture capitalist Robert Swanson and biochemist Dr. Herbert Boyer. In the early 1970s, Boyer and geneticist Stanley Cohen at Stanford University pioneered recombinant DNA technology.